ClinicalTrials.gg
RecruitingNCT07422532AID-HDUpdated Oct 19, 2026

A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis

An interventional study of Omnipod 5 and Insulin injections in Type 2 Diabetes and Chronic Kidney Disease 5D, sponsored by Imperial College London. Recruiting at 4 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 19, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Diabetes Mellitus, Type 2 by Imperial College London — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Imperial College London.

Planned enrollment
8th of 14
84 · median 117
Started
2026
with 1 other
No phase
13 of 19
6 open now
Registered
19th of 19
by date

Among the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 19th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 19 studies in Diabetes Mellitus, Type 2 by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Diabetes Mellitus, Type 2 by Imperial College London, or all of them as a file.
02

Study summary

Diabetes is the leading cause of kidney failure in the UK. Many people with diabetes and advanced kidney failure inject themselves with insulin and do finger-prick blood glucose tests. Managing diabetes in people with advanced kidney disease is challenging, with fluctuating glucose levels and an increased risk of unsafe low glucose levels. We now have continuous glucose monitors (CGM), which allow people to monitor glucose without painful fingerprick tests. CGM can be combined with insulin pumps to create automated insulin delivery systems (AID) that automatically deliver insulin to control glucose levels. AID systems are currently used in people with type 1 diabetes, but they are not used in people with type 2 diabetes. There is little information on how these systems might help people with diabetes and advanced kidney failure, and on dialysis.

This study will investigate whether automated insulin delivery can improve glucose levels and quality of life in people with type 2 diabetes treated with more than one insulin injection with advanced kidney failure and undergoing regular haemodialysis treatment. This study will be conducted in four UK centres and will be of a parallel design. We estimate that the trial will require 84 participants to be recruited, and 76 participants to be randomised. We aim for 64 participants across both groups to complete the trial. Participants will wear a glucose sensor at the start. In random order, half will be randomised to AID treatment while the other half will continue usual care augmented with continuous glucose monitoring. The duration of each treatment stage is 12 weeks. The study will last about 18 weeks for each participant. We will compare the glucose levels in the AID group with the usual care group to see if there is a difference. Questionnaires and interviews will help us understand participants' experiences. We will carefully monitor the safety of the participants.

03

Conditions studied

  • Type 2 Diabetes
  • Chronic Kidney Disease 5D

Keywords

  • Type 2 Diabetes
  • Haemodialysis
  • Chronic kidney diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Aged 18 years and older
  2. Participant has insulin-treated type 2 diabetes on more than 1 insulin injection per day or insulin pump therapy
  3. Participant has ESKD and is established on out-patient hospital-based haemodialysis treatment at least 3 times a week, via an arterio-venous fistula, graft or central venous catheter
  4. If the participant uses a CGM, the baseline time spent between 3.9 to 10 mmol/L in the last 4 weeks is \<70%
  5. For those not using CGM screening >7.0% (53 mmol/mol) and ≤ 12% (108 mmol/mol)
  6. Total daily dose of insulin is > 10 units and \<200 units per day
  7. Literate in English for safe study conduct.
  8. Willing to wear study glucose sensors and the AID system
  9. Willing to follow study-specific instructions
  10. Female participants of childbearing age should be on effective , not sexually active / or have no plans for pregnancy
  11. All patients whether transplant-wait listed or not, are eligible for inclusion.

Exclusion Criteria:

Exclusion Criteria

  1. Any other physical disease or people with known severe mental illness (psychotic disorder, bipolar disorder, dementia, substance and alcohol dependence, learning disabilities, active suicidal ideation) that are likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  2. Either current use of peritoneal dialysis or planned modality transfer (transplantation from a live donor with a confirmed date, peritoneal dialysis or conservative care) in the next 18 weeks
  3. Only treated with background (basal) insulin
  4. The participant is currently on AID or more than 2 weeks use of AID in the last 4 weeks
  5. Known or suspected allergy against insulin
  6. Treated with sulphonylureas (use of SGLT2 inhibitors are allowed)
  7. Treated with hydroxyurea (sensor interference)
  8. Presence of unstable retinopathy per Investigator's judgement
  9. Severe bilateral visual impairment
  10. Pregnancy, planned pregnancy in the next 3 months or breastfeeding current or planned use other than inhaled/ topical use. Stable long-term steroid use is not an exclusion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Placebo comparator
    Control group (Usual Care)

    Usual insulin injections

    Device: Insulin injections

  • Active comparator
    Intervention Arm

    Omnipod 5

    Device: Omnipod 5

Interventions

  • DeviceOmnipod 5

    Omnipod 5 automated insulin delivery system

  • DeviceInsulin injections

    Usual insulin injections

06

What researchers measure

Primary outcomes

  1. Time in range 3.9 to 10 mmol/l

    Glucose time in range (TIR), % of readings between 3.9 to 10.0 mmol/l based on sensor glucose levels, from randomisation to 12 weeks

    Time frame: 12 weeks

Secondary outcomes

  1. Time spent below target glucose (<3.9mmol/l)

    Time spent below target glucose (\<3.9mmol/l)

    Time frame: 12 weeks

  2. Time spent below target glucose (<3.0mmol/l)

    Time spent below target glucose (\<3.0mmol/l)

    Time frame: 12 weeks

  3. Severe hypoglycaemic episodes

    Severe hypoglycaemic episodes as defined by American Diabetes Association

    Time frame: 12 weeks

  4. Frequency of significant ketosis events (ketones >1.5)

    Frequency of significant ketosis events (ketones \>1.5)

    Time frame: 12 weeks

  5. Diabetes Treatment Satisfaction Questionnaire Score

    The DTSQ is a validated, 8-item measure that evaluates respondents' satisfaction with their diabetes treatment using a 7-point Likert scale. It consists of six questions about diabetes treatment and two questions regarding the burden of hypo- and hyperglycaemia. Treatment satisfaction is scored from 0 to 36 based on the responses to the first six questions, with higher scores indicating greater satisfaction with treatment

    Time frame: 12 weeks

  6. Quality of life (EQ-5D-5L) Score

    The EQ-5D-5L consists of two parts. The EQ-5D descriptive system is a non-disease-specific measure of health-related quality of life. Respondents evaluate their perceived health status across five dimensions, each with five levels. The results from these five dimensions can be combined into a five-digit number that describes the respondent's perceived health state. The second part is the EQ VAS, where respondents record their self-rated health on a vertical visual analogue scale with endpoints labelled 'The best health you can imagine' and 'The worst health you can imagine'.

    Time frame: 12 weeks

  7. Xerostomia Inventory (XI) Score

    The Xerostomia Inventory (XI) assesses oral dryness and comprises 11 items, each rated on a five-point Likert scale (never = 1, to very often = 5). The responses to these 11 items are summed, resulting in an individual XI score for each patient that ranges from 11 (no dry mouth) to 55 (extremely dry mouth).

    Time frame: 12 weeks

  8. Type 2 Diabetes Distress Assessment System (T2-DDAS) Score

    Type 2 Diabetes Distress Assessment System (T2-DDAS) - The T2-DDAS is a validated 8-item measure of diabetes distress, where respondents answer each question on a 5-point Likert scale. The core distress score is the average of the eight items on the core scale, with each item rated from 1 to 5. Mean score \<2.0 indicate little or no distress Mean score ≥2.0 but not more than 2.9 indicates moderate distress Mean score ≥3.0 indicate high distress Any score \> 2.0 is considered clinically significant

    Time frame: 12 weeks

  9. Frequency of significant ketosis events (ketones >3)

    Frequency of significant ketosis events (ketones \>3)

    Time frame: 12 weeks

  10. Dialysis Thirst Inventory (DTI) Score

    Dialysis Thirst Inventory (DTI) - The DTI is a questionnaire that measures perceived thirst in individuals undergoing dialysis. It contains seven items, each with a five-point Likert-type scale (never = 1, to very often = 5). The scores are summed to produce a DTI score ranging from seven (no thirst) to 35 (very thirsty).

    Time frame: 12 weeks

Other outcomes

  1. Death

    Death

    Time frame: 12 weeks

  2. Time above range > 10 mmol/L

    Time above range \> 10 mmol/L

    Time frame: 12 weeks

  3. Time above range > 13.9 mmol/L

    Time above range \> 13.9 mmol/L

    Time frame: 12 weeks

  4. Mean glucose levels

    Mean glucose levels

    Time frame: 12 weeks

  5. Coefficient of variation of glucose levels

    Coefficient of variation of glucose levels

    Time frame: 12 weeks

  6. Total Daily Dose of Insulin

    Total Daily Dose of Insulin

    Time frame: 12 weeks

  7. Ultrafiltration volume

    Ultrafiltration volume

    Time frame: 12 weeks

  8. Interdialytic weight gain

    Interdialytic weight gain

    Time frame: 12 weeks

  9. Percentage of time auto-mode use

    Percentage of time auto-mode use

    Time frame: 12 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Lu JC, Lee P, Ierino F, MacIsaac RJ, Ekinci E, O'Neal D. Challenges of Glycemic Control in People With Diabetes and Advanced Kidney Disease and the Potential of Automated Insulin Delivery. J Diabetes Sci Technol. 2024 Nov;18(6):1500-1508. doi: 10.1177/19322968231174040. Epub 2023 May 10. PubMed 37162092 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 8 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Apr 2026 → Sep 2026, primary completion Apr 2027 → May 2027 and completion Apr 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 20, 2026
StartActual
Sep 1, 2026was Apr 2026
Primary completionEst.
May 1, 2027was Apr 2027
CompletionEst.
Dec 1, 2027was Apr 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Royal Derby Hospital · Derby, United Kingdomno status→Recruiting
  • Guys and St Thomas' Hospitals · London, United Kingdomno status→Recruiting
  • Hammersmith Hospital · London, United Kingdomno status→Recruiting
  • Manchester Royal Infirmary · Manchester, United Kingdomno status→Recruiting
Oct 19, 2026
Start date
Apr 1, 2026→Sep 1, 2026 (actual)
Oct 19, 2026
Primary completion
Apr 1, 2027→May 1, 2027
Oct 19, 2026
Study completion
Apr 1, 2027→Dec 1, 2027
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Royal Derby Hospital · Derby, United Kingdomno status→Recruiting
    • Guys and St Thomas' Hospitals · London, United Kingdomno status→Recruiting
    • Hammersmith Hospital · London, United Kingdomno status→Recruiting
    • Manchester Royal Infirmary · Manchester, United Kingdomno status→Recruiting
    Start date Apr 1, 2026→Sep 1, 2026 (now actual)
    Primary completion Apr 1, 2027→May 1, 2027
    Study completion Apr 1, 2027→Dec 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07422532
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Sep 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Lalantha Leelarathna, PhD
Contact
lalantha.leelarathna@nhs.net
+44 7984477771

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion